Golden Meditech : MONTHLY UPDATE ANNOUNCEMENT ON (1) PROPOSAL FOR THE PRIVATISATION OF GOLDEN MEDITECH HOLDINGS LIMITED BY THE OFFEROR BY WAY OF A SCHEME OF ARRANGEMENT (UNDER SECTION 86 OF THE COMPANIES LAW) (2) PROPOSED WITHDRAWAL OF LISTING AND (3) SPECIAL DEAL RELATING TO THE UNDERTAKING

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.

This joint announcement appears for information purposes only and is not intended to and does not constitute, or form part of, any offer to purchase or subscribe for or an invitation to purchase or subscribe for any securities of the Offeror or the Company or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of the Company in any jurisdiction in contravention of applicable law.

Meditech Global Group Limited

(Incorporated in the British Virgin Islands

with limited liability)

MONTHLY UPDATE ANNOUNCEMENT

ON (1) PROPOSAL FOR THE PRIVATISATION OF

GOLDEN MEDITECH HOLDINGS LIMITED BY THE OFFEROR

BY WAY OF A SCHEME OF ARRANGEMENT

(UNDER SECTION 86 OF THE COMPANIES LAW)

1. 1. PROPOSED WITHDRAWAL OF LISTING AND
2. SPECIAL DEAL RELATING TO THE UNDERTAKING
   Financial Adviser to the Offeror

Independent Financial Adviser to the Company

References are made to (i) the announcement jointly issued by Golden Meditech Holdings Limited (the "Company") and Meditech Global Group Limited (the "Offeror") dated 17 June 2020 (the "Joint Announcement") in relation to, among other things, the proposed privatisation of the Company by the Offeror by way of a scheme of arrangement (under section 86 of the Companies Law) and the proposed withdrawal of listing of the shares of the Company from The Stock Exchange of Hong Kong Limited; and (ii) the announcement jointly issued by the Company and the Offeror dated 8 July 2020 in relation to the extension of time for despatch of the Scheme Document. Capitalised terms used herein shall have the same meanings as those defined in the Joint Announcement unless the context requires otherwise.

- 1 -

The Proposal will only become effective if, amongst other Conditions, the Scheme is approved by the Scheme Shareholders at the Court Meeting. A direction hearing is required for the Grand Court to issue directions to convene the Court Meeting. As at the date of this announcement, the Company has been informed by its Cayman Islands legal adviser that the direction hearing will be held on 13 August 2020 (Cayman Islands time) and the petition hearing to sanction the Scheme will be held on 9 October 2020 (Cayman Islands time). Further, the Company and the Offeror were still in the process of finalising the Scheme Document (including but not limited to the confirmation in relation to material changes).

Further announcement(s) in relation to the Proposal will be made by the Company and the Offeror as and when appropriate in accordance with the requirements of the Listing Rules and/or the Takeovers Code (as the case may be).

WARNING: Shareholders and potential investors should be aware that the implementation of the Proposal is subject to the Conditions being fulfilled or waived, as applicable, and thus the Proposal may or may not be implemented and the Scheme may or may not become effective. Shareholders and potential investors should therefore exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their stockbroker, bank manager, solicitor or other professional advisers.

By order of the board of	By order of the board of
Meditech Global Group Limited	Golden Meditech Holdings Limited
KAM Yuen	Feng Wen
Sole Director	Chairman
Hong Kong, 7 August 2020

As at the date of this joint announcement, the Board comprises five Directors. The executive Directors are Mr. Feng Wen (Chairman) and Mr. Leong Kim Chuan (Chief Executive); and the independent non-executive Directors are Mr. Gao Yue, Mr. Poon Tsz Hang and Mr. Daniel Foa.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than information relating to the Offeror or any of the Offeror Concert Parties) and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than opinions expressed by the Offeror or any of the Offeror Concert Parties) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.

As at the date of this joint announcement, (i) the sole director of the Offeror is Mr. Kam; (ii) the sole director of Bio Garden Inc. is Mr. Kam; (iii) the sole director of China In Shine Investment Limited is Ms. Fung Chit; (iv) the sole director of Asia Pacific MedTech (BVI) Limited is Ms. Gu Nana; and (v) the sole director of Famous Sino Limited is Mr. Wu Guangze.

- 2 -

Mr. Kam (in his capacity as the sole director of the Offeror) accepts full responsibility for the accuracy of the information contained in this joint announcement (other than information relating to the Group) and confirm, having made all reasonable inquiries, that to the best of his knowledge, opinions expressed in this joint announcement (other than opinions expressed by the Group) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.

Mr. Kam (in his capacity as the sole director of Bio Garden Inc.), Ms. Fung Chit (in her capacity as the sole director of China In Shine Investment Limited), Ms. Gu Nana (in her capacity as the sole director of Asia Pacific MedTech (BVI) Limited) and Mr. Wu Guangze (in his capacity as the sole director of Famous Sino Limited) jointly and severally accepts full responsibility for the accuracy of the information contained in this joint announcement (other than information relating to the Group) and confirm, having made all reasonable inquiries, that to the best of her/his knowledge, opinions expressed in this joint announcement (other than opinions expressed by the Group) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.

- 3 -